[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates

November 2016 | 27 pages | ID: AAC381D84B4EN
La Merie Publishing

US$ 225.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Anti-CD22 Immunotherapeutics in:

October 2016 R&D and Business Tracker for Antibody-Drug Conjugates

This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates.

Featured presentations of October 2016 include the pipeline of CD22-targeted immunotherapeutics, the profile of US biotech Asana Biosciences and the profile of anti-nectin-6 antibody-drug conjugate AGS67E from Astellas Pharma.

The October 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:

R&D and Technology Tracker
  • Pipeline changes
  • Regulatory news
  • Technology validations
  • Manufacturing news
Business Tracker for:
  • Company updates
  • Collaboration
  • Licensing
  • Merger & acquisitions
  • Financing
Clinical Trial Tracker

Scientific Publication Tracker

Featured ADC Profile: AGS67E

Featured Company Profile: Asana Biosciencess

Featured Target Pipeline: Anti-CD22 Immunotherapeutics

CD-22Targeted Immunotherapeutics include:
  • Naked Antibodies & Combinations
  • Radioimmunotherapeutics
  • Immunotoxins
  • Antibody-Drug Conjugates
  • Autologous CAR T-Cells
Information about the anti-CD22 Immunotherapeutics pipeline is provided in a tabular format and fully referenced.


Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Customized Update Service:

The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.

More Publications